$140B CDMO Pharma Sector, India Just Getting Started | Best STOCKS to watch | Sector का राजा

Описание: Looking for the best stocks to buy now or the top sectors to invest in 2025? In this episode of Sector Ka Raja, Dipan Mehta breaks down the pharma sector analysis with a special focus on the rising CDMO (Contract Development and Manufacturing Organizations) industry – the backbone of global pharmaceutical innovation.

Discover why this booming segment is among the best sectors to invest in India for the long term, and why top Indian pharma stocks like Divi’s Labs, Suven Pharma, Syngene International and Blue Jet Healthcare are making headlines. We’ll explore how this sector remains resilient even against U.S. tariffs—and what makes it a strong pick for future growth.

Whether you're hunting for pharma stocks to buy now, evaluating the best sector stocks to buy now, or simply curious about the pharma sector share performance, this video is your complete guide to smart investing in 2025 and beyond.

#sectorinvestment #beststockstobuynow #stockstobuynow #stockstowatch #beststocks2025

====================
Try PaisaSmart Chatbot Here: https://wa.me/918808990978

📈Invest in our Smallcase - Paisasmart Wealth Builder: https://paisasmart.smallcase.com/smal...
====================

Suggested Playlists:
▶️ पैसा Maker:    • पैसा Maker Stocks by Dipan Mehta  
▶️ Sector का राजा:    • Sector का राजा By Dipan Mehta  
▶️ Paisasmart Smallcase:    • Dipan Mehta's Model Portfolio : PaisaSmart...  

====================

Follow Us On:
Instagram:   / paisasmart  
LinkedIn:   / paisasmart  
Facebook:   / 100089490661437  
Spotify: https://open.spotify.com/show/5be355f...

====================

Note: The captions appearing in this video are auto-generated and may contain inaccuracies. Please excuse any errors.

Disclaimer: This podcast is produced by Elixir Equities Pvt. Ltd., a SEBI registered research analyst, registration number INA000004787. The information provided in this podcast is for educational and informational purposes only and should not be considered as investment advice. Investment in securities market are subject to market risks.
For full disclaimer click on the link:
https://elixirequities.com/disclaimers